Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome

References

• Iijima K, Sako M, Nozu K. Rituximab treatment for nephrotic syndrome in children. Curr Pediatr Rep. 2015;3:71–77.
   PubMedGoogle Scholar
• Kurasawa T, Nagasawa H, Nishi E. Successful treatment of class IV + V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. Intern Med. 2013;52:1125–1130.
   PubMed Web of Science ®Google Scholar
• Hirano D, Fujinaga S, Nishizaki N. The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome. Clin Nephrol. 2012;77:510–512.
   PubMed Web of Science ®Google Scholar
• Lai WL, Yeh TH, Chen PM. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc. 2015;114:102–111.
   PubMed Web of Science ®Google Scholar
• Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061–1068.
   PubMed Web of Science ®Google Scholar
• Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007;22:2183–2193.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tsuruga K, Watanabe S. Persistent immature glomeruli in a girl with refractory nephrotic syndrome. Nephrology (Carlton). 2013;18:77–78.
   PubMed Web of Science ®Google Scholar
• Ito S, Kamei K, Ogura M. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:257–264.
   PubMed Web of Science ®Google Scholar
• Azib S, Macher MA, Kwon T, et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:927–932.
   PubMed Web of Science ®Google Scholar
• Zagury A, de Oliveira AL, deMoraes CA, et al. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:915–920.
   PubMed Web of Science ®Google Scholar
• Iijima K, Sako M, Nozu K. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet. 2014;384:1273–1281.
   PubMed Web of Science ®Google Scholar
• Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C. Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience. Nephron Extra. 2014;4:8–17.
   PubMedGoogle Scholar
• Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephritic syndrome. Pediatrics. 2009;124:747–757.
   PubMed Web of Science ®Google Scholar
• Sun L, Xu H, Shen Q, et al. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai. World J Pediatr. 2014;10:59–63.
   PubMed Web of Science ®Google Scholar
• Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007;50:248–256.
   PubMed Web of Science ®Google Scholar
• Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton). 2007;12:576–581.
   PubMed Web of Science ®Google Scholar
• Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008;52:699–705.
   PubMed Web of Science ®Google Scholar
• Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29:1570–1577.
   PubMed Web of Science ®Google Scholar
• Narváez J, Díaz-Torné C, Magallares B. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One. 2015;10:e0123392.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kaneko Y, Atsumi T, et al. Clinical and radiographic effects after 52-week of adding tocilizumab or switching to tocilizumab in rheumatoid arthritis patients with inadequate response to methotrexate: results from a prospective randomized controlled study (SURPRISE study) [abstract]. Ann Rheum Dis. 2014;73:686.
   Web of Science ®Google Scholar
• Pham T, Fautrel B. Recommendations of the French Society for rheumatology regarding TNF alpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine. 2007;74:638–646.
   PubMed Web of Science ®Google Scholar
• Vu D, Shah T, Ansari J, Naraghi R, Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc. 2015;47:394–398.
   PubMed Web of Science ®Google Scholar
• Soukup T, Dosedel M, Nekvindova J, Toms J, Vlcek J, Pavek P. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:426–432.
   PubMed Web of Science ®Google Scholar
• Ciszek M, Mucha K, Foroncewicz B. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient–a case report. Ann Transplant. 2014;19:60–63.
   PubMed Web of Science ®Google Scholar
• Shahin AA, El-Agha S, El-Azkalany GS. The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients. Clin Rheumatol. 2014;33:925–930.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao Y, Zhang Z. Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria. Nephrology (Carlton). 2014;19:94–100.
   PubMed Web of Science ®Google Scholar
• Yang S, Xie L, Xue W. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. Nephrology (Carlton). 2013;18:615–622.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y, Liu G, Li J, Xu R, Huang J. Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease. Clin Nephrol. 2013;80:121–129.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Dayer JM. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841–849.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Germain M. Leflunomide: an immune modulating drug that may have a role in controlling secondary infections with review of its mechanisms of action. J Drugs Dermatol. 2015;14:230–234.
   PubMed Web of Science ®Google Scholar
• Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004;26:447–459.
   PubMed Web of Science ®Google Scholar
• Manna K, Agarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependant nuclear factorkappa B factor activation and gene expression. J Immunol. 1999;162:2095–2102.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J. Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol. 2014;32:275–284.
   PubMed Web of Science ®Google Scholar
• Wc GC, Xu XD, Huang Q, Wu H. Leflunomide: friend or foe for systemic lupus erythematosus? RheumatolInt. 2013;33:273–276.
   Web of Science ®Google Scholar